Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714181 | 0.87 | CYP1A2 (0.51) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL855444 | 0.85 | CYP1A2 (0.50) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL2070116 | 0.84 | CYP1A2 (0.49) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL393999 | 0.83 | DAGLA (0.42) | FBP1 | |
| SCHEMBL27603649 | 0.81 | CYP1A2 (0.46) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL15932112 | 0.81 | CYP1A2 (0.46) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL2113445 | 0.81 | CYP1A2 (0.46) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL31434686 | 0.80 | CYP1A2 (0.45) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL369268 | 0.80 | CYP1A2 (0.51) | CYP1A2NLRP3ALDH1A1MAPTKMT2A | |
| SCHEMBL2070169 | 0.80 | CYP1A2 (0.55) | CYP1A2NLRP3ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| EP-1771432-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
| WO-2000053589-A1 | PROCESS FOR PREPARING OXAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | CYP1A2 1951/4885NLRP3 661/4885ALDH1A1 2417/4885 |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | CYP1A2 1951/4885NLRP3 661/4885ALDH1A1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.